Caption Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-12,300
Closed -$3.46M 1683
2024
Q3
$2.61M Buy
+12,300
New +$3.15M 0.04% 481
2023
Q4
Sell
-43,300
Closed -$6.32M 1536
2023
Q3
$6.32M Sell
43,300
-9,400
-18% -$1.77M 0.1% 259
2023
Q2
$12.2M Buy
52,700
+1,000
+2% +$271K 0.22% 117
2023
Q1
$12.5M Buy
51,700
+45,182
+693% +$12.3M 0.24% 96
2022
Q4
$1.89M Buy
+6,518
New +$637K 0.03% 573
2021
Q1
Sell
-1,114
Closed -$123K 1265
2020
Q4
$123K Sell
1,114
-11,048
-91% -$1.35M ﹤0.01% 866
2020
Q3
$1.44M Buy
+12,162
New +$1.32M 0.03% 528
2019
Q2
Sell
-9,000
Closed -$964K 758
2019
Q1
$1.13M Buy
+9,000
New +$1.12M 0.06% 334
2018
Q4
Sell
-2,200
Closed -$340K 554
2018
Q3
$471K Buy
+2,200
New +$552K 0.03% 416

Other funds holding MDGL

Caption Management's MDGL Position: Q4 2024 in Review

Caption Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2024, closing a stake of 12,300 shares — an estimated $3.46M sold.

Caption Management first reported a position in MDGL in Q3 2018 and held it in 9 quarters. The position peaked at $12.5M in Q1 2023. 283 funds tracked by Wall St. Rank hold MDGL as of Q4 2024.

  • Caption Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 12,300 Madrigal Pharmaceuticals shares in Q4 2024, an estimated $3.46M.
  • Caption Management first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 9 quarters.
  • Caption Management's Madrigal Pharmaceuticals position peaked at $12.5M in Q1 2023.
  • 283 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.